Condition

Metabolism and Nutrition Disorder

ClinicalTrials.gov condition label

Clinical trials42
Recruiting1
Common interventions25
Lead sponsors shown7

Clinical trials

42 shown
The Biological Rhythm of Human MetaboliteNCT03669809 · 2011-05-01
RECRUITING
Energy Metabolism Profiles Over Weight-loss and Eating ResponsesNCT05785221 · 2023-03-02
ACTIVE_NOT_RECRUITING
The Effect of Vegetarian Diet on Patients With Metabolic Associated Fatty Liver DiseaseNCT05443581 · 2022-07-01
UNKNOWN
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)NCT05024032 · 2021-09-01
COMPLETED
The Effect of High vs. Moderate Protein Consumption on Human HealthNCT04156165 · 2019-11-01
COMPLETED
Research Study of a New Medicine (NNC9204-1706) in People With Overweight or ObesityNCT03661879 · 2018-09-12
COMPLETED
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or ObesityNCT03548935 · 2018-06-04
COMPLETED
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or ObesityNCT03548987 · 2018-06-04
COMPLETED
A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or ObesityNCT03479892 · 2018-03-13
COMPLETED
Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or ObesityNCT03308721 · 2017-10-16
COMPLETED
Awareness, Care and Treatment in Obesity ManagementNCT03235102 · 2017-08-03
COMPLETED
Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With ObesityNCT03095807 · 2017-03-20
COMPLETED
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal InsulinNCT02963922 · 2017-02-06
COMPLETED
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist SettingNCT02963935 · 2017-02-06
COMPLETED
First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or ObesityNCT03015207 · 2017-01-06
COMPLETED
In-market Utilisation of Liraglutide Used for Weight Management in EuropeNCT02967757 · 2016-12-22
COMPLETED
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or OverweightNCT02958085 · 2016-11-04
COMPLETED
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.NCT02941042 · 2016-10-10
COMPLETED
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With ObesityNCT02918279 · 2016-09-29
COMPLETED
Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With ObesityNCT02870231 · 2016-08-18
COMPLETED
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With ObesityNCT02835235 · 2016-07-26
COMPLETED
A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.NCT02717858 · 2016-03-16
COMPLETED
A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 YearsNCT02696148 · 2016-03-14
COMPLETED
Improving Glucose and Lipid Metabolism Through Caloric Restriction Using Diet or Surgery (CRUDOS)NCT02988011 · 2016-02-28
UNKNOWN
Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi SyndromeNCT02527200 · 2015-11-09
COMPLETED
Awareness, Care & Treatment in Obesity Management (ACTION) StudyNCT03223493 · 2015-10-29
COMPLETED
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy SubjectsNCT02568306 · 2015-10-05
COMPLETED
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes MellitusNCT02453711 · 2015-10-01
COMPLETED
Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male SubjectsNCT02300844 · 2014-12-01
COMPLETED
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male SubjectsNCT02235961 · 2014-09-04
COMPLETED
Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectorsNCT02207348 · 2014-08-01
COMPLETED
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With PlaceboNCT02079870 · 2014-03-06
COMPLETED
A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 YearsNCT01789086 · 2013-02-01
COMPLETED
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep ApnoeaNCT01557166 · 2012-06-07
COMPLETED
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - DiabetesNCT01272232 · 2011-06-01
COMPLETED
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetesNCT01272219 · 2011-06-01
COMPLETED
A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy VolunteersNCT01044108 · 2010-01-05
TERMINATED
A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese VolunteersNCT00978393 · 2009-09-16
COMPLETED
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - MaintenanceNCT00781937 · 2008-10-30
COMPLETED
Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese VolunteersNCT00728455 · 2008-07-01
WITHDRAWN
Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female VolunteersNCT00665665 · 2007-11-01
TERMINATED
The Effect of Liraglutide on Body Weight in Obese Subjects Without DiabetesNCT00422058 · 2007-01-10
COMPLETED

Common interventions

PlaceboDRUG30liraglutideDRUG17semaglutideDRUG4NNC9204-0530DRUG3NNC0174-0833DRUG2NNC0194-0499DRUG2No treatment givenOTHER2'2-0453DRUG1CMS Intensive Behavior TherapyBEHAVIORAL1dietary interventionBEHAVIORAL1Gastric by-pass surgeryPROCEDURE1General lifestyle and nutritional educationBEHAVIORAL1Liraglutide 3.0 mgDRUG1Low-caloric dietDIETARY_SUPPLEMENT1Maintenance-ActiveOTHER1Maintenance-ControlOTHER1NNC 0070-0002-0182DRUG1NNC 0070-0002-0349DRUG1NNC 0070-0002-0453DRUG1NNC0165-1562DRUG1NNC9204-1177DRUG1NNC9204-1177 A 1.0 mg/mLDRUG1NNC9204-1706DRUG1NNC9204-1706 ADRUG1orlistatDRUG1

Trial status mix

COMPLETED35
TERMINATED2
UNKNOWN2
ACTIVE_NOT_RECRUITING1
RECRUITING1
WITHDRAWN1

Phase mix

PHASE121
PHASE311
NA4
PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.